Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Gibson

Showing results (121-130 of 126) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 126 results.
Neurobiology of Aging|December 29, 2009
A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's diseaseRejko Krüger, Manu Sharma, Olaf Riess, et al.
Rheumatology (Oxford, England)|November 14, 2025
The 2025 British Society for Rheumatology guideline for the prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugsKatie Bechman, Kaiyang Song, Abhishek Abhishek, et al.
Neurobiology of Aging|July 26, 2011
Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's diseaseManu Sharma, Demetrius M Maraganore, John P A Ioannidis, et al.
Annals of Neurology|March 11, 2011
Independent and joint effects of the MAPT and SNCA genes in Parkinson diseaseAlexis Elbaz, Owen A Ross, John P A Ioannidis, et al.
The Lancet. Neurology|September 3, 2011
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control studyOwen A Ross, Alexandra I Soto-Ortolaza, Michael G Heckman, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 6, 2013
Population-specific frequencies for LRRK2 susceptibility variants in the Genetic Epidemiology of Parkinson's Disease (GEO-PD) ConsortiumMichael G Heckman, Alexandra I Soto-Ortolaza, Jan O Aasly, et al.
Pageof 13

Showing results (121-130 of 126) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 126 results.
Neurobiology of Aging|December 29, 2009
A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's diseaseRejko Krüger, Manu Sharma, Olaf Riess, et al.
Rheumatology (Oxford, England)|November 14, 2025
The 2025 British Society for Rheumatology guideline for the prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugsKatie Bechman, Kaiyang Song, Abhishek Abhishek, et al.
Neurobiology of Aging|July 26, 2011
Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's diseaseManu Sharma, Demetrius M Maraganore, John P A Ioannidis, et al.
Annals of Neurology|March 11, 2011
Independent and joint effects of the MAPT and SNCA genes in Parkinson diseaseAlexis Elbaz, Owen A Ross, John P A Ioannidis, et al.
The Lancet. Neurology|September 3, 2011
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control studyOwen A Ross, Alexandra I Soto-Ortolaza, Michael G Heckman, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 6, 2013
Population-specific frequencies for LRRK2 susceptibility variants in the Genetic Epidemiology of Parkinson's Disease (GEO-PD) ConsortiumMichael G Heckman, Alexandra I Soto-Ortolaza, Jan O Aasly, et al.
Pageof 13